Fertility and Sterility
Volume 75, Issue 2 , Pages 316-323 , February 2001

Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women

Results of this study were presented in part at the 8th World Congress of Gynecological Endocrinology, Florence, Italy, December 6–9, 2000, and the Winter Meeting of the British Society for the Study of Fertility and the Nederlands-Vlaamse Vereiniging voor Fertiliteitsstudies, Utrecht, The Netherlands, December 15–16, 2000.

  • Katharina Erb, M.D.

      Affiliations

    • Clinical Research and Development, ASTA Medica AG, Frankfurt am Main, Germany, and Dinox bv, Nijmegen, The Netherlands
    • Corresponding Author InformationReprint requests and current address: Katharina Erb, M.D., Applied Clinical Pharmacology Services, Philippsring 11, 55252 Mainz-Kastel, Germany (FAX: +49-6134-180468 )
    • ,
  • Christine Klipping, M.D.

      Affiliations

    • Clinical Research and Development, ASTA Medica AG, Frankfurt am Main, Germany, and Dinox bv, Nijmegen, The Netherlands
    • ,
  • Ingrid Duijkers, M.D.

      Affiliations

    • Clinical Research and Development, ASTA Medica AG, Frankfurt am Main, Germany, and Dinox bv, Nijmegen, The Netherlands
    • ,
  • Birgit Pechstein, Ph.D.

      Affiliations

    • Clinical Research and Development, ASTA Medica AG, Frankfurt am Main, Germany, and Dinox bv, Nijmegen, The Netherlands
    • ,
  • Armin Schueler, M.S.

      Affiliations

    • Clinical Research and Development, ASTA Medica AG, Frankfurt am Main, Germany, and Dinox bv, Nijmegen, The Netherlands
    • ,
  • Robert Hermann (M.D)

      Affiliations

    • Clinical Research and Development, ASTA Medica AG, Frankfurt am Main, Germany, and Dinox bv, Nijmegen, The Netherlands

Received 25 May 2000 ,Revised 18 August 2000 ,Accepted 18 August 2000.

References 

  1. Beckers T, Reiländer H, Hilgard P. Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997;251:17–23
  2. Reissmann T, Engel J, Kutscher B, Bernd M, Hilgard P, Peukert M, et al.  Cetrorelix. Drugs Future. 1994;19:228–237
  3. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T, et al.  Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9:788–791
  4. Leroy I, d’Acremont M, Brailly-Tabard S, Frydman R, de Mouzon J, Bouchard P. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (cetrorelix) postpones the luteinizing hormone (LH) surge (further evidence for the role of GnRH during the LH surge). Fertil Steril. 1994;62:461–467
  5. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroyey P. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67:917–922
  6. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer (a dose finding study 3 versus 2 mg). Hum Reprod. 1998;13:2411–2414
  7. Felberbaum R, Diedrich K. Ovarian stimulation for in-vitro fertilization/intracytoplasmatic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues (agonists and antagonists). Hum Reprod. 1999;14:207–221
  8. Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmüller-Winzen H, Schüler A, et. al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 2000;264:29–32.
  9. Devroey P. GnRH antagonist. Fertil Steril. 2000;73:15–17
  10. Csernus VJ, Szende B, Groot K, Redding TW, Schally AV. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1,D-Phe(pCl)2,3-(3-pyridyl)-D-Ala3,D-Cit6,D-Ala10] LHRH. Arzneimittelforschung. 1990;40:111–118
  11. Veldhuis JD, Carlson ML, Johnson ML. The pituitary gland secrets in bursts (appraising the nature of glandular secretors impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations). Proc Natl Acad Sci USA. 1987;84:7686–7690
  12. Oberyé JJL, Mannaerts BMJL, Huismann JA, Timmer CJ. Pharmacokinetics and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril. 1999;72:1006–1012
  13. Hall JE, Whitcomb RW, Rivier JE, Vale WW, Crowley WF. Differential regulation of luteinizing hormone, follicle-stimulating hormone and free α-subunit secretion from the gonadotrope by gonadotropin releasing hormone (GnRH) (evidence from the use of two GnRH antagonists). J Clin Endocrinol Metabol. 1990;70:328–335
  14. Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324:93–103
  15. Schally AV. LH-RH analogues (I. Their impact on reproductive medicine). Gynecol Endocrinol. 1999;13:401–409
  16. Friedman AJ, Benacerraf B, Harrison-Atlas D, Gleason R, Barbieri RL, Schiff I. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989;51:251–256
  17. Bouchard P, Fauser CJM. Gonadotropin-releasing hormone antagonist (new tools vs. old habits). Fertil Steril. 2000;73:18–20
  18. Fraser HM, Groome NP, McNeilly AS. Follicle-stimulating hormone-inhibin B interactions during the follicular phase of the primate menstrual cycle revealed by gonadotropin-releasing hormone antagonist and antiestrogen treatment. J Clin Endocrinol Metabol. 1999;84:1365–1369
  19. Duijkers IJM, Klipping C, Willemsen WNP, Krone D, Schneider E, Niebch G, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist cetrorelix in healthy female volunteers. Hum Reprod. 1998;13:2392–2398
  20. Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, Derendorf H. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol. 2000;40:1–9
  21. Oberyé JJL, Mannaerts BMJL, Kleijn HJ, Timmer CJ. Pharmacokinetics and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999;72:1001–1005

☆ Supported by ASTA Medica AG, Frankfurt am Main, Germany.

PII: S0015-0282(00)01702-7

Fertility and Sterility
Volume 75, Issue 2 , Pages 316-323 , February 2001

Article Tools

* Image Usage & Resolution